{
Samarth Kulkarni

People

}
insider sales and hedge fund activity at crispr therapeutics raise eyebrows
CRISPR Therapeutics insiders have sold 50,382 shares worth $2.74 million in the last 90 days, with insiders owning 4.10% of the company. Institutional investors hold 69.20% of the stock, while analysts maintain a "Hold" rating, with a consensus target price of $77.93. The company's recent earnings report showed a loss of $1.01 per share, exceeding expectations, but revenue fell short at $0.60 million.
MarketBeat
CRISPR Therapeutics AG USA James Kasinger Samarth Kulkarni
Finance & Economy, Market Report
15:09 20.12.2024
crispr therapeutics shares hit new low amid mixed analyst ratings
Larson Financial Group LLC increased its stake in CRISPR Therapeutics by 95.5% in Q2, now holding 565 shares valued at $31,000. Other institutional investors also made significant investments, with ownership among them at 69.20%. CRISPR Therapeutics, focused on gene-editing for serious diseases, recently hit a 52-week low of $40.61, with analysts giving it a consensus "Hold" rating and an average price target of $77.93.
MarketBeat
CRISPR Therapeutics AG USA James Kasinger Samarth Kulkarni
Finance & Economy, Market Report
12:18 19.12.2024
crispr therapeutics experiences drop in short interest and mixed analyst ratings
CRISPR Therapeutics AG (NASDAQ:CRSP) experienced a 6.4% decline in short interest in November, totaling 18,150,000 shares. Analysts have mixed ratings, with a consensus "Hold" and a target price of $77.93, while CEO Samarth Kulkarni sold 30,000 shares, reducing his stake by 13.24%. The company reported a quarterly EPS of ($1.01), surpassing estimates, but revenue fell short at $0.60 million.
MarketBeat
CRISPR Therapeutics AG USA James Kasinger Samarth Kulkarni
Finance & Economy, Market Report
04:20 17.12.2024
insider trades and stock performance update for crisper therapeutics
CRISPR Therapeutics' CEO sold shares at an average price of $46.28, totaling $198,680.04, reducing their ownership by 1.86%. General Counsel James R. Kasinger also sold shares, resulting in a 1.71% decrease in their holdings. Insiders have sold 50,382 shares valued at $2,744,179 in the last three months, with 4.10% of the stock owned by insiders. The company reported a quarterly loss of $1.01 EPS, exceeding estimates, while analysts maintain a "Hold" rating with a consensus target price of $77.93.
MarketBeat
CRISPR Therapeutics AG USA James Kasinger Samarth Kulkarni
Finance & Economy, Market Report
09:52 15.12.2024
institutional investors increase stakes in crisper therapeutics amid stock fluctuations
Larson Financial Group LLC and GPS Wealth Strategies Group LLC significantly increased their stakes in CRISPR Therapeutics during the second quarter, with institutional investors now owning 69.20% of the company. The stock recently hit a 52-week low of $43.23, and analysts have mixed ratings, with a consensus "Hold" and an average target price of $77.93. In its latest earnings report, CRISPR posted a loss of $1.01 per share, beating estimates but falling short on revenue expectations.
MarketBeat
CRISPR Therapeutics AG USA James Kasinger Samarth Kulkarni
Finance & Economy, Market Report
20:55 14.12.2024
analysts lower earnings estimates for crispr therapeutics amid mixed ratings
CRISPR Therapeutics (NASDAQ: CRSP) has seen a reduction in Q2 2025 earnings estimates to ($1.48) per share, with a full-year consensus of ($5.17) per share. Analysts have mixed ratings, with two sell, eight hold, and nine buy ratings, while the stock is currently trading at $47.78, down 1.8%. Institutional investors hold 69.20% of the company, reflecting ongoing interest despite recent insider selling.
MarketBeat
CRISPR Therapeutics AG CHE James Kasinger Samarth Kulkarni
Finance & Economy, Market Report
13:37 12.12.2024
insider trading activity and earnings forecast for crispr therapeutics
William Blair forecasts CRISPR Therapeutics will report FY2024 earnings of ($4.66) per share, slightly better than the consensus estimate of ($5.17). The company recently posted Q3 earnings of ($1.01) per share, exceeding expectations, but reported revenues significantly below estimates. Analysts maintain a "Hold" rating on the stock, with a mixed outlook reflected in various price targets.
MarketBeat
CRISPR Therapeutics AG Stanley Corwin James Kasinger Samarth Kulkarni Show more
Finance & Economy, Market Report
13:21 11.12.2024
crispr therapeutics faces mixed analyst ratings and insider stock sales
CRISPR Therapeutics holds a consensus "Hold" rating with an average target price of $74.94. CEO Samarth Kulkarni recently sold 30,000 shares at $55.62, reducing his stake by 13.24%. The company reported a quarterly loss of $1.01 per share, surpassing estimates, with revenue of $0.60 million. Insider sales totaled 50,382 shares valued at $2.74 million in the last 90 days, while institutional investors own 69.20% of the stock. The stock traded at $51.94, with a 52-week range of $43.42 to $91.10.
MarketBeat
CRISPR Therapeutics AG USA James Kasinger Samarth Kulkarni
Finance & Economy, Market Report
10:33 06.12.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Corporate Responsibility & ESG Central Bank Actions Decentralized Finance (DeFi) Innovations Cryptocurrency & Blockchain Regulations Tokenomics and Crypto Economics Banking Regulations Cryptocurrency Regulations Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Funding Rounds & Investments Mergers & Acquisitions Cryptocurrency Developments SEC & Financial Compliance Inflation Rates & CPI Data Real Estate Investments Shareholder Activism
Countries:
USA CHE JPN AUS CAN IND GBR DEU AUT CHN HKG RUS LIE SAU BHR FRA ARG COL FIN NLD
Companies:
Coinbase Global, Inc. Ripples USD Solana USD BlackRock, Inc. Ethereum USD NVIDIA Corporation Cardano USD Tesla, Inc. Apple Inc. Credit Suisse Real Estate Fund Siat MicroStrategy Incorporated Amazon.com, Inc. Sumitomo Corp Google Inc. Bitwise Bitcoin ETF Chainlink USD Palantir Technologies Inc. Tether USDt CNY VAT Group AG Northern Star Resources Ltd
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Canadian Dollar Colombian Peso Singapore Dollar Indian Rupee
People:
Ali Martinez Donald Trump Michael J. Saylor Elon Musk Charles Hoskinson Bill Gates Fred Thiel Jack Dorsey Jacob King Brian Armstrong Aaron Green Gary Gensler Karin Keller-Sutter Mario Nawfal Alan Santana Richard Schueler Roger J. Hamilton Steven Rossi Jane Dietze Brian P. Brooks

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.